Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Bottom-Up

Xuanzhu Biopharmaceutical / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/xuanzhu-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:44117:1" rel="noopener">Xuanzhu Biopharmaceutical (XUANZHU HK)</a> entered into a licensing and supply agreement with Boston Oncology giving them rights to develop, register and commercialize Bireociclib and Dirozalkib within the licensed territory.</li>
<li>Xuanzhu’s revenue in 2025 stood at RMB 51.8M (up 72% YoY). R&amp;D expenses witnessed a decrease of 33%, while losses narrowed by 56% YoY to RMB 245.5M in 2025.</li>
<li>2026 will be an inflection point for the company with all three core products fully commercialized, but will not be enough for the company to establish a sustainable market play.</li>
</ul>



Xuanzhu Biopharmaceutical (XUANZHU HK) entered into a licensing and supply agreement with Boston Oncology giving them rights to develop, register and commercialize Bireociclib and Dirozalkib within the licensed territory.
Xuanzhu’s revenue in 2025 stood at RMB 51.8M (up 72% YoY). R&amp;D expenses witnessed a decrease of 33%, while losses narrowed by 56% YoY to RMB 245.5M in 2025.
2026 will be an inflection point for the company with all three core products fully commercialized, but will not be enough for the company to establish a sustainable market play.


Xuanzhu Biopharmaceutical: Out Licensing Agreement A Positive, But Not Enough for a Sustainable Play